To reduce treatment delays, pathologists should initiate biomarker testing reflexively. Waiting for a medical oncologist to order tests at a first visit is a system failure, wasting critical time and risking the need to retrieve archived samples.

A practical, gold-standard clinical test for oncologists to quickly screen for LEMS is to ask a patient to stand from a chair without using their arms. An inability to do so is a strong, immediate indicator of proximal leg weakness—a hallmark of LEMS—and should trigger a more comprehensive workup.

The technology and breadth of molecular testing panels for GIST are rapidly evolving. A patient whose tumor tested negative for driver mutations in the past should be considered for re-testing with current, broader panels. This may uncover previously undetectable alterations like FGFR translocations and open up new treatment options.

Clinicians ordering "NGS for lung" often misunderstand that Next-Generation Sequencing alone does not cover all actionable biomarkers, such as PD-L1 or HER2. This requires pathologists to interpret the clinician's intent and order a more comprehensive and appropriate test panel.

To effectively diagnose LEMS, healthcare systems must implement systemic changes rather than relying on individual clinician awareness. This includes using tumor boards for unexplained weakness, treating VGCC results as critical lab values requiring a direct handoff, and building bundled order sets for testing and referrals to create a reliable diagnostic pathway.

Experts express concern that the paraneoplastic syndrome LEMS is frequently missed in SCLC patients. Its primary symptom, proximal muscle weakness, is often attributed to the cancer itself or treatment side effects, leading clinicians to overlook the specific diagnostic test for this distinct and potentially treatable condition.

A standard nerve conduction study will often miss LEMS because it doesn't include the necessary protocols. To ensure an accurate diagnosis, the referral must explicitly state to 'evaluate for LEMS' or 'presynaptic neuromuscular junction dysfunction.' This instruction triggers the required rapid stimulation and exercise components essential for detection.

Clinicians must not rule out LEMS based on a negative VGCC antibody test alone, as 5-15% of true LEMS patients are seronegative. If the clinical exam and electrophysiological findings fit the diagnosis, the workup must continue regardless of the blood test result. The complete clinical picture is paramount.

Oncologists should be highly suspicious of LEMS when a patient's functional decline is disproportionate to their cancer's response to treatment. If imaging shows tumors are shrinking but the patient is getting weaker, this mismatch is a critical signal that a distinct paraneoplastic process is at play and warrants immediate investigation.